Product names like GLOW, Wolverine, and KLOW sound precise. They are not. These are seller-coined marketing labels for multi-component lyophilised vials—not pharmacopoeial standards, not United States Adopted Names, and not International Nonproprietary Names. The same name can refer to materially different formulations depending on the seller, the batch, and even the week.
This article explains how these names work, where the variability comes from, and why the absence of combination-specific evidence matters for anyone reading a blend claim.
How market names become unstable
The blend atlas index documents why no authority defines these compositions. No regulatory body—FDA, EMA, or any pharmacopoeia—has established a standard for GLOW, Wolverine, or any other marketed blend name. A seller can reformulate without notice, and the same name can persist across radically different products.
The GLOW blend page illustrates the pattern. GLOW is marketed as a three-component combination of GHK-Cu, BPC-157, and TB-500. Across observed batches, the GHK-Cu content ranges from approximately 34 to 62 milligrams per vial—a nearly twofold difference. BPC-157 and TB-500 amounts also shift across sellers and batches. No standard formulation exists.
The Wolverine blend page adds another layer of ambiguity. The TB-500 component can refer to either the full-length 43-amino-acid thymosin beta-4 sequence or a 7-amino-acid fragment. These differ roughly fivefold in molecular weight, which means a label claiming "ten milligrams TB-500" represents a fundamentally different molar quantity depending on which form is used. Most sellers do not specify which variant their product contains.
KLOW, documented on its blend page, extends GLOW by adding a fourth component—the tripeptide KPV. The name itself is a marketing acronym. GHK-Cu loading ranges from 25 to 50 milligrams across sellers, and one variant omits TB-500 entirely while retaining the KLOW name.
The blend registry captures 11 entries, each with a standardization status of "none." From the foundational Wolverine pair to the four-component KLOW and the boundary cases like AOD-9604/HGH Frag 176-191 (two variant fragments of the same growth-hormone C-terminal tail, often confused and marketed interchangeably), the unifying feature is the absence of any external standard.
Why combination evidence is absent
The most important finding across all documented blends is also the simplest: no named peptide blend has published combination-specific efficacy data. The blend atlas index states this explicitly as the central limitation across all 11 entries.
The GLOW triple combination (GHK-Cu + BPC-157 + TB-500) has no published controlled study testing it against its individual components or against placebo. The claimed rationale—GHK-Cu for matrix remodelling, BPC-157 for angiogenesis, TB-500 for cell migration—is a mechanistic extrapolation from separate preclinical literatures. The same pattern holds for Wolverine (BPC-157 + TB-500) and KLOW (four components, four non-overlapping pathways hypothesised).
This is not a gap that inference can fill. Combination effects can be synergistic, additive, antagonistic, or simply absent, and no study design that tests components separately can predict the outcome of their co-administration. The molar ratios in blends also deviate from anything tested in component studies. In a typical KLOW blend, the tripeptides GHK-Cu and KPV account for more than 93% of the molar content, yet each component's separate literature was developed at entirely different ratios.
What the atlas captures and what it cannot
The blend atlas records observed formulations from commercial sources with explicit verification limits. It does not verify purity, confirm the identity of the material in a given vial, or test stability. The evidence tables separate individual-component data from combination data and explicitly mark which cells have no published support.
Safety uncertainties compound with each added component. Any adverse effect in a pre-blended vial cannot be attributed to one component. Fixed ratios prevent independent adjustment. Co-lyophilisation and post-rehydration stability have not been independently characterised for any of these multi-component mixtures.
Reading blend claims with precision
When encountering a named blend, the first question is not "what does it do" but "what exactly is in this vial?" The answer depends on the seller, the batch, and the molecular form of each component—none of which is captured by the marketing name alone. The second question is whether the combination has been studied as a combination. For every blend documented in this atlas, the answer is no.
The distinction between a marketing label and a standardised formulation is central to evidence literacy. A name that sounds like a product is not the same as a product that has been defined, tested, and regulated.
For a deeper look at how evidence grades, claim tables, and verification dates work across the atlas, see the evidence grading methodology.